JP2018500372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500372A5 JP2018500372A5 JP2017534909A JP2017534909A JP2018500372A5 JP 2018500372 A5 JP2018500372 A5 JP 2018500372A5 JP 2017534909 A JP2017534909 A JP 2017534909A JP 2017534909 A JP2017534909 A JP 2017534909A JP 2018500372 A5 JP2018500372 A5 JP 2018500372A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- compound according
- halo
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 82
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 42
- 125000001475 halogen functional group Chemical group 0.000 claims description 41
- -1 C 1 -C 6 -alkyl Chemical group 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 102000014150 Interferons Human genes 0.000 claims description 10
- 108010050904 Interferons Proteins 0.000 claims description 10
- 229940079322 interferon Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- YYCDGEZXHXHLGW-UHFFFAOYSA-N 6-amino-9-benzyl-2-(2-methoxyethoxy)-7h-purin-8-one Chemical group C12=NC(OCCOC)=NC(N)=C2NC(=O)N1CC1=CC=CC=C1 YYCDGEZXHXHLGW-UHFFFAOYSA-N 0.000 claims description 4
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 4
- 108010047761 Interferon-alpha Proteins 0.000 claims description 4
- 102000006992 Interferon-alpha Human genes 0.000 claims description 4
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 4
- 102000003996 Interferon-beta Human genes 0.000 claims description 4
- 108090000467 Interferon-beta Proteins 0.000 claims description 4
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 4
- 229960003130 interferon gamma Drugs 0.000 claims description 4
- 229960001388 interferon-beta Drugs 0.000 claims description 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 4
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims description 2
- 229940122806 Cyclophilin inhibitor Drugs 0.000 claims description 2
- 102000001493 Cyclophilins Human genes 0.000 claims description 2
- 108010068682 Cyclophilins Proteins 0.000 claims description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 2
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 2
- 108700024845 Hepatitis B virus P Proteins 0.000 claims description 2
- 229940123066 Polymerase inhibitor Drugs 0.000 claims description 2
- 229940124942 Recombivax HB Drugs 0.000 claims description 2
- 108700033496 Recombivax HB Proteins 0.000 claims description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 2
- 229940124615 TLR 7 agonist Drugs 0.000 claims description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 2
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 2
- 229960004748 abacavir Drugs 0.000 claims description 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 229960001997 adefovir Drugs 0.000 claims description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000000234 capsid Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960000724 cidofovir Drugs 0.000 claims description 2
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 2
- 229960005319 delavirdine Drugs 0.000 claims description 2
- 229960002656 didanosine Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960003804 efavirenz Drugs 0.000 claims description 2
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 2
- 229960000366 emtricitabine Drugs 0.000 claims description 2
- 229960000980 entecavir Drugs 0.000 claims description 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims description 2
- 229960002049 etravirine Drugs 0.000 claims description 2
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 claims description 2
- 229960004396 famciclovir Drugs 0.000 claims description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002963 ganciclovir Drugs 0.000 claims description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229960001627 lamivudine Drugs 0.000 claims description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 claims description 2
- FEFIBEHSXLKJGI-UHFFFAOYSA-N methyl 2-[3-[[3-(6-amino-2-butoxy-8-oxo-7h-purin-9-yl)propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate Chemical compound C12=NC(OCCCC)=NC(N)=C2NC(=O)N1CCCN(CC=1C=C(CC(=O)OC)C=CC=1)CCCN1CCOCC1 FEFIBEHSXLKJGI-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 229960000689 nevirapine Drugs 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 229960000329 ribavirin Drugs 0.000 claims description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
- 229960001203 stavudine Drugs 0.000 claims description 2
- 229960004556 tenofovir Drugs 0.000 claims description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 2
- 229940093257 valacyclovir Drugs 0.000 claims description 2
- 229960002149 valganciclovir Drugs 0.000 claims description 2
- 230000029302 virus maturation Effects 0.000 claims description 2
- 229960000523 zalcitabine Drugs 0.000 claims description 2
- 229960002555 zidovudine Drugs 0.000 claims description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462097835P | 2014-12-30 | 2014-12-30 | |
| US62/097,835 | 2014-12-30 | ||
| US201562163150P | 2015-05-18 | 2015-05-18 | |
| US62/163,150 | 2015-05-18 | ||
| PCT/US2015/068099 WO2016109689A2 (en) | 2014-12-30 | 2015-12-30 | Derivatives and methods of treating hepatitis b infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500372A JP2018500372A (ja) | 2018-01-11 |
| JP2018500372A5 true JP2018500372A5 (https=) | 2019-05-23 |
| JP6713465B2 JP6713465B2 (ja) | 2020-06-24 |
Family
ID=56163427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534909A Expired - Fee Related JP6713465B2 (ja) | 2014-12-30 | 2015-12-30 | Ｂ型肝炎感染症治療のための誘導体及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (11) | US9550779B2 (https=) |
| EP (1) | EP3240787A4 (https=) |
| JP (1) | JP6713465B2 (https=) |
| KR (1) | KR20170118706A (https=) |
| CN (1) | CN107531691A (https=) |
| AU (2) | AU2015373996B2 (https=) |
| CA (1) | CA2972434A1 (https=) |
| MX (1) | MX383929B (https=) |
| RU (1) | RU2742305C2 (https=) |
| WO (3) | WO2016109684A2 (https=) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| EA038942B1 (ru) | 2012-08-28 | 2021-11-12 | Янссен Сайенсиз Айрлэнд Юси | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b |
| HUE034820T2 (en) | 2013-02-28 | 2018-02-28 | Janssen Sciences Ireland Uc | Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B |
| EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| EA035500B1 (ru) | 2013-05-17 | 2020-06-25 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b |
| TWI651300B (zh) | 2013-05-17 | 2019-02-21 | 健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| DK3024819T3 (en) | 2013-07-25 | 2018-06-06 | Janssen Sciences Ireland Uc | GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| KR102290189B1 (ko) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도 |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| JP6553059B2 (ja) | 2014-02-05 | 2019-07-31 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｈｂｖ感染の治療のための併用療法 |
| WO2015118057A1 (en) | 2014-02-06 | 2015-08-13 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| RU2742305C2 (ru) | 2014-12-30 | 2021-02-04 | Новира Терапьютикс, Инк. | Производные и способы лечения инфекций гепатита в |
| EP3271019A1 (en) | 2015-03-19 | 2018-01-24 | Novira Therapeutics Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| HK1259410A1 (zh) | 2015-09-29 | 2019-11-29 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| JP6904970B2 (ja) | 2016-03-07 | 2021-07-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| SG10202011827YA (en) | 2016-04-15 | 2021-01-28 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
| CN109843296A (zh) | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | 乙型肝炎抗病毒药剂 |
| JP6935434B2 (ja) | 2016-06-29 | 2021-09-15 | ノヴィラ・セラピューティクス・インコーポレイテッド | オキサジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用 |
| AU2017290755B2 (en) | 2016-06-29 | 2021-07-01 | Novira Therapeutics, Inc. | Diazepinone derivatives and their use in the treatment of hepatitis B infections |
| CN109415368B (zh) * | 2016-07-14 | 2021-04-30 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的羧基6,7-二氢-4H-吡唑并[1,5-a]吡嗪化合物 |
| EP3484886B1 (en) | 2016-07-14 | 2020-03-04 | Hoffmann-La Roche AG | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| WO2018011160A1 (en) * | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| EP3484883B1 (en) * | 2016-07-14 | 2020-04-15 | H. Hoffnabb-La Roche Ag | Novel tetrahydropyrazolopyridine compounds for the treatment of infectious diseases |
| HRP20220144T1 (hr) | 2016-09-09 | 2022-04-15 | Novartis Ag | Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora |
| IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| US10952978B2 (en) | 2017-08-28 | 2021-03-23 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| JP2021501764A (ja) | 2017-11-02 | 2021-01-21 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｂ型肝炎ウイルス（ｈｂｖ）に対して有効な新規高活性アミノチアゾール置換インドール−２−カルボキサミド |
| MA50520A (fr) | 2017-11-02 | 2020-09-09 | Aicuris Gmbh & Co Kg | Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb) |
| CN111247131B (zh) * | 2017-11-16 | 2022-02-18 | 正大天晴药业集团股份有限公司 | 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物 |
| EP3710455A1 (en) * | 2017-11-17 | 2020-09-23 | Novartis AG | Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b |
| TW201936192A (zh) | 2017-12-06 | 2019-09-16 | 美商因那塔製藥公司 | B 型肝炎抗病毒試劑 |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CA3083797A1 (en) * | 2017-12-21 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Isoxazole compounds for the treatment of diseases associated with hbv infections |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
| CA3090125A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| WO2019191166A1 (en) * | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| CN110437132B (zh) * | 2018-05-04 | 2022-04-01 | 上海长森药业有限公司 | 双并杂环核衣壳抑制剂及其药物用途 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| EP3856178B1 (en) | 2018-09-28 | 2026-03-11 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
| BR112021006403A2 (pt) * | 2018-10-05 | 2021-07-06 | Univ Emory | agentes monômeros e multiméricos anti-hbv |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| AU2019373679A1 (en) | 2018-11-02 | 2021-05-27 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4H-thiazolo(5,4-c)pyridines active against the hepatitis B virus (HBV) |
| AR117189A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) |
| AR116946A1 (es) * | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
| PY1991608A (es) * | 2018-11-02 | 2022-02-10 | Aicuris Gmbh & Co Kg | Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazina activas contra el virus de la hepatitis b (vhb) |
| PY1991603A (es) * | 2018-11-02 | 2020-09-17 | Aicuris Gmbh & Co Kg | Nueva 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole -2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| UY38435A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN111333590B (zh) * | 2018-12-18 | 2022-05-17 | 沈阳中化农药化工研发有限公司 | 一种异恶唑烷盐酸盐的制备方法 |
| MX2021010145A (es) | 2019-02-22 | 2021-09-14 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| KR102707808B1 (ko) | 2019-03-07 | 2024-09-19 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| KR20210139319A (ko) * | 2019-03-14 | 2021-11-22 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv 감염 또는 hbv-유도성 질환의 치료에 사용하기 위한 융합 고리 피리미돈 유도체 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| SG11202111236UA (en) | 2019-04-30 | 2021-11-29 | Aicuris Gmbh & Co Kg | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
| PH12021552749A1 (en) | 2019-04-30 | 2022-07-11 | Aicuris Gmbh & Co Kg | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) |
| SG11202111493WA (en) | 2019-04-30 | 2021-11-29 | Aicuris Gmbh & Co Kg | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
| PH12021552733A1 (en) | 2019-04-30 | 2023-01-16 | Aicuris Gmbh & Co Kg | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) |
| MA55879A (fr) | 2019-05-06 | 2022-03-16 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| CN113825758B (zh) * | 2019-05-14 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型 |
| UY38705A (es) * | 2019-05-23 | 2020-12-31 | Irbm S P A | Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| WO2020243135A1 (en) * | 2019-05-28 | 2020-12-03 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives |
| BR112021023651A2 (pt) * | 2019-05-28 | 2022-04-12 | Janssen Sciences Ireland Unlimited Co | Azepinas como moduladores de montagem de capsídeo de hbv |
| CN113939512A (zh) * | 2019-05-28 | 2022-01-14 | 爱尔兰詹森科学公司 | 作为抗病毒剂的稠合的杂环衍生物 |
| EP3976619A1 (en) * | 2019-05-28 | 2022-04-06 | Janssen Sciences Ireland Unlimited Company | Fused heterocycle derivatives as capsid assembly modulators |
| US20220235051A1 (en) * | 2019-05-28 | 2022-07-28 | Janssen Sciences Ireland Unlimited Company | Di-fluoro azepanes as hbv capsid assembly modulators |
| JP2022534495A (ja) * | 2019-05-28 | 2022-08-01 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 融合複素環式誘導体 |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021023662A1 (en) | 2019-08-02 | 2021-02-11 | Janssen Sciences Ireland Unlimited Company | Pyrazolo[4,3-c]pyridine compounds for use in the treatment of hbv infection |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| CN113264931B (zh) * | 2020-02-17 | 2022-06-07 | 成都先导药物开发股份有限公司 | 一种1,4,6,7-四氢-5H-吡唑并[4,3-c]吡啶衍生物的制备方法 |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| BR112022019077A2 (pt) * | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
| GB202103704D0 (en) * | 2021-03-17 | 2021-04-28 | Pathios Therapeutics Ltd | Compounds |
| JP7755319B2 (ja) * | 2020-06-05 | 2025-10-16 | パシオス セラピューティクス リミテッド | Ｇｐｒ６５のモジュレーターとしてのｎ－（フェニルアミノカルボニル）テトラヒドロ－イソキノリン及び関連する化合物 |
| PE20230779A1 (es) | 2020-08-07 | 2023-05-09 | Gilead Sciences Inc | Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico |
| TW202227435A (zh) * | 2020-09-11 | 2022-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之稠合環嘧啶酮衍生物 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN116744927A (zh) * | 2020-12-02 | 2023-09-12 | 杨森科学爱尔兰无限公司 | 稠合杂环衍生物及其在治疗hbv感染中的用途 |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| WO2025117677A1 (en) * | 2023-11-29 | 2025-06-05 | Actio Biosciences, Inc. | Heterocyclic compounds useful as kcnt1 inhibitors |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK27383A (da) * | 1982-02-17 | 1983-08-18 | Lepetit Spa | Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner |
| ES2349762T3 (es) | 2000-08-10 | 2011-01-11 | Pfizer Italia S.R.L. | Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden. |
| HK1052509B (en) * | 2000-08-14 | 2007-09-07 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted pyrazole |
| MXPA03001960A (es) * | 2000-09-06 | 2004-03-18 | Johnson & Johnson | Un metodo para tratar alergias. |
| JP5039268B2 (ja) * | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| US6897208B2 (en) * | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| JP2005528443A (ja) * | 2002-05-30 | 2005-09-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｊａｋキナーゼおよびｃｄｋ２プロテインキナーゼのインヒビター |
| CA2482838A1 (en) * | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Pyrazole compounds and pharmaceutical compositions containing the compound |
| CA2493625A1 (en) | 2002-07-25 | 2004-02-19 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| JP2005537290A (ja) * | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
| ATE546452T1 (de) * | 2003-09-23 | 2012-03-15 | Vertex Pharma | Pyrazolopyrrolderivate als proteinkinaseinhibitoren |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| JP5433690B2 (ja) * | 2008-06-25 | 2014-03-05 | ブリストル−マイヤーズ スクイブ カンパニー | 抗−ｈｉｖ薬としてのジケト縮合アゾロピペリジンおよびアゾロピペラジン |
| EP2370437B1 (en) * | 2008-11-25 | 2013-09-04 | Nerviano Medical Sciences S.r.l. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
| KR101787116B1 (ko) * | 2009-01-28 | 2017-10-18 | 케러 테라퓨틱스, 인코포레이티드 | 바이시클릭 피라졸로-헤테로사이클 |
| JP2013501804A (ja) * | 2009-08-12 | 2013-01-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | カテプシンｓ阻害剤の調製プロセス |
| US20130178475A1 (en) * | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| US9242981B2 (en) * | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP2654748B1 (en) * | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| KR101316101B1 (ko) * | 2011-05-26 | 2013-10-11 | 연세대학교 산학협력단 | Ｐｔｋ 6의 활성 억제용 조성물 및 이를 이용한 암 예방 및 치료용 조성물 |
| KR20140075723A (ko) * | 2011-09-12 | 2014-06-19 | 사노피 | 인다닐-치환된 4,5,6,7-테트라하이드로-1H-피라졸로[4,3,c]피리딘, 약물로서 그의 용도, 및 그를 포함한 약제학적 제제 |
| MX2014003181A (es) * | 2011-09-16 | 2015-08-05 | Sanofi Sa | 4,5,6,7-tetrahidro-1h-pirazolo [4,3-c] piridinas sustituidas, su uso como medicamento y preparaciones farmacéuticas que las comprenden. |
| AU2011376721B2 (en) * | 2011-09-16 | 2017-06-08 | Sanofi | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| EP2968304B1 (en) * | 2013-03-14 | 2018-10-10 | The Trustees of Columbia University in the City of New York | 4-phenylpiperidines, their preparation and use |
| RU2742305C2 (ru) | 2014-12-30 | 2021-02-04 | Новира Терапьютикс, Инк. | Производные и способы лечения инфекций гепатита в |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
-
2015
- 2015-12-30 RU RU2017126995A patent/RU2742305C2/ru active
- 2015-12-30 WO PCT/US2015/068091 patent/WO2016109684A2/en not_active Ceased
- 2015-12-30 CA CA2972434A patent/CA2972434A1/en not_active Abandoned
- 2015-12-30 JP JP2017534909A patent/JP6713465B2/ja not_active Expired - Fee Related
- 2015-12-30 US US14/984,654 patent/US9550779B2/en not_active Expired - Fee Related
- 2015-12-30 US US14/984,325 patent/US9518057B2/en not_active Expired - Fee Related
- 2015-12-30 KR KR1020177020897A patent/KR20170118706A/ko not_active Withdrawn
- 2015-12-30 CN CN201580077237.2A patent/CN107531691A/zh active Pending
- 2015-12-30 WO PCT/US2015/068099 patent/WO2016109689A2/en not_active Ceased
- 2015-12-30 MX MX2017008720A patent/MX383929B/es unknown
- 2015-12-30 AU AU2015373996A patent/AU2015373996B2/en not_active Ceased
- 2015-12-30 EP EP15876275.7A patent/EP3240787A4/en not_active Withdrawn
- 2015-12-30 WO PCT/US2015/068059 patent/WO2016109663A2/en not_active Ceased
- 2015-12-30 US US14/984,293 patent/US9527845B2/en not_active Expired - Fee Related
-
2016
- 2016-11-09 US US15/347,468 patent/US10093669B2/en not_active Expired - Fee Related
- 2016-11-15 US US15/351,851 patent/US9890161B2/en not_active Expired - Fee Related
- 2016-12-12 US US15/375,652 patent/US10077264B2/en not_active Expired - Fee Related
-
2017
- 2017-12-15 US US15/843,598 patent/US10189835B2/en not_active Expired - Fee Related
-
2018
- 2018-07-02 US US16/024,954 patent/US10538519B2/en not_active Expired - Fee Related
- 2018-08-31 US US16/118,760 patent/US10544141B2/en not_active Expired - Fee Related
- 2018-12-20 US US16/226,780 patent/US10556904B2/en not_active Expired - Fee Related
-
2019
- 2019-12-03 US US16/702,069 patent/US20200181142A1/en not_active Abandoned
-
2020
- 2020-09-15 AU AU2020233640A patent/AU2020233640A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500372A5 (https=) | ||
| JP2017504626A5 (https=) | ||
| JP2018510159A5 (https=) | ||
| RU2016138735A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| RU2017126995A (ru) | Производные и способы лечения инфекций гапатита в | |
| JP2019511542A5 (https=) | ||
| De Clercq | Antivirals: past, present and future | |
| HRP20201075T1 (hr) | 4,6-diamino-pirido[3,2-d]pirimidinski spojevi i njihova upotreba kao modulatora receptora sličnih tolu | |
| JP2010526834A5 (https=) | ||
| Mathé et al. | L-nucleoside enantiomers as antivirals drugs: a mini-review | |
| CN107427514B (zh) | 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗 | |
| JP2010514768A5 (https=) | ||
| JP2012519691A5 (https=) | ||
| JP2013523765A5 (https=) | ||
| TWI740910B (zh) | 非環抗病毒劑 | |
| JP2017203033A5 (https=) | ||
| HRP20210027T1 (hr) | Ciklički dinukleotidni spojevi | |
| JP2010528987A5 (https=) | ||
| RU2006109491A (ru) | Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств | |
| AR075584A1 (es) | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. | |
| JP2019526562A (ja) | Ｈｂｖキャプシドアセンブリ阻害剤とヌクレオシ（チ）ド類似体の併用療法 | |
| RU2016122908A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| Simons et al. | Recent advances in antiviral nucleoside and nucleotide therapeutics | |
| HK1255463A1 (zh) | Hbv衣壳组装抑制剂和干扰素的组合疗法 | |
| JP2015526448A5 (https=) |